Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.5 USD | +0.35% | +5.81% | +17.38% |
May. 03 | GSK : DZ Bank remains Neutral | ZD |
May. 03 | GSK plc : Back on track |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.38% | 88.72B | - | ||
+26.08% | 662B | C+ | ||
+21.85% | 546B | B | ||
-4.77% | 359B | C+ | ||
+16.97% | 323B | B- | ||
+5.69% | 290B | C+ | ||
+13.68% | 234B | B+ | ||
+3.65% | 198B | B- | ||
-11.12% | 194B | A+ | ||
+8.08% | 167B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- GSK Stock
- GSK Stock
- Ratings GSK plc